A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Trial Profile

A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-017
  • Sponsors Merck & Co
  • Most Recent Events

    • 05 Jun 2018 Results including data from an expansion cohort (n=24; as of 21 Jun 2017), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to a Merck & Co media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2018.
    • 19 Jan 2018 Planned primary completion date changed from 20 Jan 2018 to 6 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top